Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ASH 2018 /
Daratumumab found to increase PFS in patients with transplant-ineligible newly diagnosed multiple myeloma

1st - 4th Dec 2018

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 04.12.18
Views: 257
Rating:

Prof Thierry Facon - Hôpital Claude Huriez, Lille, France

Prof Thierry Facon speaks to ecancer at ASH 2018 about results from the DARA trial.

He explains that the trial has found that daratumumab increases PFS in patients with transplant-ineligible multiple myeloma.

Prof Facon added that the trial is important as it has the potential to establish daratumumab as the new standard of care for patients with transplant-ineligible newly diagnosed multiple myeloma.

Read more about this work here

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation